The Effects of Risperidone and Olanzapine on Thinking

This study has been completed.

Sponsor:

Collaborator:

Janssen, LP

Information provided by:

Department of Veterans Affairs

ClinicalTrials.gov Identifier:

NCT00108368

First received: April 14, 2005

Last updated: January 20, 2009

Last verified: September 2007

History of Changes

Tracking Information
First Received Date ^ICMJE	April 14, 2005
Last Updated Date	January 20, 2009
Start Date ^ICMJE	October 2003
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00108368 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	The Effects of Risperidone and Olanzapine on Thinking
Official Title ^ICMJE	The Cognitive Effects of Risperidone and Olanzapine
Brief Summary	The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition. Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 4
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Bio-availability Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment
Condition ^ICMJE	Schizophrenia Psychotic Disorders
Intervention ^ICMJE	Drug: Risperidone Drug: Olanzapine
Study Arm (s)	Not Provided
Publications *	Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct;164(10):1585-92.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	Not Provided
Completion Date	March 2006
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: Diagnosed with schizophrenia disorder by a DSM IV. Competent to sign informed consent No history of poor response to Risperdal and Zyprexa No organic brain disease Exclusion Criteria: Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.
Gender	Both
Ages	18 Years to 60 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00108368
Other Study ID Numbers ^ICMJE	MHBS-057-00S
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Department of Veterans Affairs
Collaborators ^ICMJE	Janssen, LP
Investigators ^ICMJE	Not Provided
Information Provided By	Department of Veterans Affairs
Verification Date	September 2007
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top